Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL XR 15 vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile.
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Amphetamine is primarily metabolized in the liver via cytochrome P450 enzymes, including CYP2D6, to various oxidative and deaminated metabolites. Aromatic hydroxylation produces p-hydroxyamphetamine and p-hydroxynorephedrine. Some metabolism also occurs via monoamine oxidase (MAO).
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Amphetamine is approximately 20% bound to plasma proteins, primarily albumin.
16% (primarily albumin).
Volume of distribution for amphetamine is about 3-4 L/kg, indicating extensive tissue distribution. The large Vd contributes to the long terminal half-life.
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral bioavailability of amphetamine from ADDERALL XR is approximately 90-100% relative to an oral solution; the extended-release formulation has a bioavailability similar to immediate-release tablets when administered orally.
Oral IR: ~90%; ER: ~90%.
GFR 15-30 m L/min: reduce dose by 50%; GFR <15 m L/min: use with caution, maximum dose 30 mg daily; hemodialysis: not recommended.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
Children 6-12 years: initial 10 mg once daily, increase by 5-10 mg weekly up to 30 mg/day; adolescents 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Start at 10 mg once daily, increase slowly by 5-10 mg every 2 weeks; monitor cardiovascular status and cognitive function; consider lower maintenance doses (20-30 mg daily) due to increased sensitivity.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
WARNING: ABUSE, MISUSE, AND ADDICTION. ADDERALL XR has a high potential for abuse, which can lead to tolerance, dependence, and serious cardiovascular or psychiatric adverse events. Misuse may cause sudden death or serious cardiovascular events.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious cardiovascular events including sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate should be monitored, increased risk of hypertension and tachycardia.,May exacerbate psychiatric disorders including pre-existing psychosis, mania, or bipolar disorder; emergence of new psychotic or manic symptoms.,Long-term suppression of growth in children; monitor growth during treatment.,Risk of serotonin syndrome when co-administered with serotonergic drugs.,Risk of seizures in patients with a history of seizures.,Visual disturbances including difficulty with accommodation and blurred vision.
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Hypersensitivity to amphetamine products or any component of the formulation,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
Avoid high-fat meals as they delay absorption and reduce peak concentration. Avoid acidic foods (e.g., citrus fruits, cola, vinegar) close to dosing, as they may decrease absorption. Do not consume alcohol while taking Adderall XR.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (cardiac, orofacial clefts) based on limited human data; amphetamines shown to cause developmental toxicity in animal studies. Second/third trimester: Risk of premature delivery, low birth weight, neonatal withdrawal syndrome (irritability, feeding difficulties).
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Excreted into breast milk; M/P ratio approximately 2.6-7.5 for dextroamphetamine. Not recommended due to potential for adverse effects on infant (insomnia, irritability, feeding problems, weight loss). American Academy of Pediatrics considers use compatible with caution, but alternative treatments preferred.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
Pregnancy may increase clearance of amphetamines (e.g., 30-50% increase due to enhanced hepatic metabolism and renal blood flow), potentially requiring dose adjustments. However, avoid use during pregnancy unless benefit outweighs risk; if necessary, monitor clinical response and consider dose increase based on efficacy/toxicity.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
Adderall XR 15 is a once-daily extended-release formulation of amphetamine salts. Monitor for cardiovascular events; check blood pressure and heart rate at baseline and periodically. Avoid use in patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias. Use with caution in patients with a history of substance abuse. Do not crush or chew capsules; sprinkle contents on applesauce if needed. Onset of action is 1-2 hours with duration of 10-12 hours.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow capsule whole; do not crush or chew. If needed, open capsule and sprinkle contents on a spoonful of applesauce, swallow immediately without chewing.,Avoid taking late in the day to prevent insomnia.,Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache.,This drug has a high potential for abuse and dependence; keep in a safe place.,Report any signs of heart problems: chest pain, shortness of breath, fainting.,Monitor growth in children; height and weight should be checked during treatment.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL XR 15 vs ADDERALL 20, answered by our medical review team.
ADDERALL XR 15 is a CNS Stimulant that works by ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL XR 15 and ADDERALL 20 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL XR 15 is: Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL XR 15 and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL XR 15 is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (cardiac, orofacial clefts) based on limited human data; amphetamines shown to cause deve. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.